The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric
patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch�…

The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1)
immune checkpoints are negative regulators of T-cell immune function. Inhibition of these�…

Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a�…

Cancer immunotherapies have shown sustained clinical responses in treating non-small-
cell lung cancer,–, but efficacy varies and depends in part on the amount and properties of�…

Neoantigens arise from mutations in cancer cells and are important targets of T cell-
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a�…

KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS�…

Melanoma, a skin cancer associated with high mortality rates, is highly radio-and
chemotherapy resistant but can also be very immunogenic. These circumstances have led to�…

Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are
broadly efficacious, improved outcomes have been observed in patients with high PD-L1�…

In vitro cancer cultures, including three-dimensional organoids, typically contain exclusively
neoplastic epithelium but require artificial reconstitution to recapitulate the tumor�…

Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features
of cholangiocyte differentiation: cholangiocarcinomas are categorized according to�…